Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROCinIT neoadjuvant intratumoral ipilimumab plus systemic nivolumab for resectable oral cancer
2025-523617-29-01Phase 2Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab and nivolumab in Oral Mucosal Carcinoma, sponsored by Amsterdam University Medical Center. Planned start Jul 2026; status: authorised.
02
Drugs
ipilimumabnivolumab
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on 2025-523617-29-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523617-29-01.